Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the seven ratings firms that are currently covering the company, MarketBeat reports. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $58.60.

AGIO has been the topic of several recent research reports. Scotiabank lowered their price target on shares of Agios Pharmaceuticals from $74.00 to $71.00 and set a "sector outperform" rating on the stock in a research note on Friday, May 2nd. Wall Street Zen downgraded Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Monday, May 19th.

Agios Pharmaceuticals Stock Performance

NASDAQ AGIO traded down $0.21 during trading on Friday, hitting $33.26. The stock had a trading volume of 338,543 shares, compared to its average volume of 650,735. Agios Pharmaceuticals has a 12 month low of $23.42 and a 12 month high of $62.58. The company's 50-day moving average price is $31.27 and its two-hundred day moving average price is $32.07. The company has a market capitalization of $1.93 billion, a PE ratio of 2.96 and a beta of 0.73.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($1.55) EPS for the quarter, topping analysts' consensus estimates of ($1.80) by $0.25. Agios Pharmaceuticals had a net margin of 1,798.26% and a negative return on equity of 2.75%. The business had revenue of $8.73 million for the quarter, compared to analyst estimates of $9.86 million. As a group, equities analysts anticipate that Agios Pharmaceuticals will post -6.85 earnings per share for the current fiscal year.

Insider Buying and Selling at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, CEO Brian Goff sold 18,700 shares of the stock in a transaction on Tuesday, June 24th. The shares were sold at an average price of $33.54, for a total value of $627,198.00. Following the completion of the sale, the chief executive officer owned 105,401 shares in the company, valued at $3,535,149.54. This trade represents a 15.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Sarah Gheuens sold 2,909 shares of the company's stock in a transaction dated Tuesday, June 24th. The shares were sold at an average price of $33.54, for a total transaction of $97,567.86. Following the completion of the sale, the insider directly owned 56,988 shares in the company, valued at approximately $1,911,377.52. The trade was a 4.86% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 36,455 shares of company stock valued at $1,165,424 in the last 90 days. Company insiders own 4.93% of the company's stock.

Institutional Trading of Agios Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the business. Summit Investment Advisors Inc. boosted its stake in shares of Agios Pharmaceuticals by 7.1% during the 4th quarter. Summit Investment Advisors Inc. now owns 5,913 shares of the biopharmaceutical company's stock worth $194,000 after acquiring an additional 394 shares during the period. PNC Financial Services Group Inc. boosted its position in Agios Pharmaceuticals by 16.2% during the first quarter. PNC Financial Services Group Inc. now owns 3,582 shares of the biopharmaceutical company's stock worth $105,000 after purchasing an additional 499 shares during the period. Federated Hermes Inc. boosted its position in Agios Pharmaceuticals by 4.4% during the fourth quarter. Federated Hermes Inc. now owns 13,691 shares of the biopharmaceutical company's stock worth $450,000 after purchasing an additional 582 shares during the period. Alliancebernstein L.P. increased its holdings in shares of Agios Pharmaceuticals by 1.2% in the fourth quarter. Alliancebernstein L.P. now owns 61,500 shares of the biopharmaceutical company's stock valued at $2,021,000 after purchasing an additional 708 shares during the last quarter. Finally, Atria Investments Inc raised its position in shares of Agios Pharmaceuticals by 6.9% in the fourth quarter. Atria Investments Inc now owns 11,365 shares of the biopharmaceutical company's stock valued at $373,000 after purchasing an additional 737 shares during the period.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.